Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.

PURPOSE The Ontario Breast Screening Program expanded in July 2011 to screen women age 30 to 69 years at high risk for breast cancer with annual magnetic resonance imaging (MRI) and digital mammography. To the best of our knowledge, this is the first organized screening program for women at high risk for breast cancer. PATIENTS AND METHODS Performance measures after assessment were compared with screening results for 2,207 women with initial screening examinations. The following criteria were used to determine eligibility: known mutation in BRCA1, BRCA2, or other gene predisposing to a markedly increased risk of breast cancer, untested first-degree relative of a gene mutation carrier, family history consistent with hereditary breast cancer syndrome and estimated personal lifetime breast cancer risk ≥ 25%, or radiation therapy to the chest (before age 30 years and at least 8 years previously). RESULTS The recall rate was significantly higher among women who had abnormal MRI alone (15.1%; 95% CI, 13.8% to 16.4%) compared with mammogram alone (6.4%; 95% CI, 5.5% to 7.3%). Of the 35 breast cancers detected (16.3 per 1,000; 95% CI, 11.2 to 22.2), none were detected by mammogram alone, 23 (65.7%) were detected by MRI alone (10.7 per 1,000; 95% CI, 6.7 to 15.8), and 25 (71%) were detected among women who were known gene mutation carriers (30.8 per 1,000, 95% CI, 19.4 to 43.7). The positive predictive value was highest for detection based on mammogram and MRI (12.4%; 95% CI, 7.3% to 19.3%). CONCLUSION Screening with annual MRI combined with mammography has the potential to be effectively implemented into an organized breast screening program for women at high risk for breast cancer. This could be considered an important management option for known BRCA gene mutation carriers.

[1]  A R Padhani,et al.  Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) , 2005, The Lancet.

[2]  F. O'Malley,et al.  Performance measures from 10 years of breast screening in the Ontario Breast Screening Program, 1990/91 to 2000 , 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[3]  J. Klijn,et al.  Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[4]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[5]  Holly Neibergs,et al.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 , 2004 .

[6]  Etta D Pisano,et al.  Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. , 2012, JAMA.

[7]  Medical Advisory Secretariat Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis. , 2010, Ontario health technology assessment series.

[8]  Constantine Gatsonis,et al.  Screening women at high risk for breast cancer with mammography and magnetic resonance imaging , 2005, Cancer.

[9]  M. Stovall,et al.  Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. , 2003, JAMA.

[10]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[11]  M. Yaffe,et al.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Nelson,et al.  Screening for Breast Cancer , 2003 .

[13]  K. Hemminki,et al.  Risk of breast cancer in families of multiple affected women and men , 2012, Breast Cancer Research and Treatment.

[14]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[15]  E. Warner,et al.  Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer. , 1999, Canadian family physician Medecin de famille canadien.

[16]  D. Stoppa-Lyonnet,et al.  Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Maximilian Reiser,et al.  Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Evans,et al.  Risk assessment and management of high risk familial breast cancer , 2002, Journal of medical genetics.

[19]  Laura Cortesi,et al.  Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study): Final Results , 2011, Investigative radiology.

[20]  R. Fimmers,et al.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A S Whittemore,et al.  Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. , 1997, American journal of human genetics.

[22]  R. Goldbohm,et al.  Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease , 2001, The Lancet.

[23]  J. Austoker,et al.  The psychological impact of mammographic screening on women with a family history of breast cancer—a systematic review , 2005, Psycho-oncology.

[24]  N. Day,et al.  Family history and the risk of breast cancer: A systematic review and meta‐analysis , 1997, International journal of cancer.

[25]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[26]  Harry J de Koning,et al.  Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition , 2006, Cancer.

[27]  J. Boyd,et al.  Hereditary breast cancer. , 2001, Current problems in surgery.

[28]  Jan Lubinski,et al.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers , 2008, International journal of cancer.

[29]  K. Heimdal,et al.  Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group. , 1999, Disease markers.

[30]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[31]  W. Thompson,et al.  The genetic attributable risk of breast and ovarian cancer , 1996, Cancer.

[32]  D. Eccles,et al.  Guidelines for a genetic risk based approach to advising women with a family history of breast cancer , 2000, Journal of medical genetics.

[33]  Sarah A. Edwards,et al.  Digital compared with screen-film mammography: performance measures in concurrent cohorts within an organized breast screening program. , 2013, Radiology.

[34]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[35]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .

[36]  S. Narod Screening of women at high risk for breast cancer. , 2011, Preventive medicine.

[37]  J. Chang-Claude,et al.  Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. , 1998, European journal of cancer.

[38]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[39]  J. Chang-Claude,et al.  Guidelines for Follow-Up of Women at High Risk for Inherited Breast Cancer: Consensus Statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer , 2002, Disease markers.

[40]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.